UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): July 12, 2005




                           DRAGON PHARMACEUTICAL INC.
                           --------------------------
             (Exact name of registrant as specified in its charter)


           Florida                        0-27937                65-0142474
           -------                        -------                ----------
State or Other Jurisdiction of    (Commission File Number)     (IRS Employer
        Incorporation)                                       Identification No.)

       1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                   V6E 2E9
         ----------------------------                  -------
(Address of Principal Executive Offices)             (Zip Code)


                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 4a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))


<PAGE>

SECTION 4.  MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

Item 4.01 Changes in Registrant's Certifying Accountant
-------------------------------------------------------

     Dragon  Pharmaceutical  Inc.  (the  "Registrant")  was  informed  that  its
independent  registered  public  accounting  firm of Moore Stephens Ellis Foster
Ltd. ("Moore Stephens"),  merged with and into Ernst & Young LLP on May 5, 2005.
On July 10, 2005,  the  Registrant's  board of directors  formally  approved the
engagement of Ernst & Young as the Registrant's  independent  registered  public
accounting  firm  for  2005.  On  July  12,  2005,  the  former  Moore  Stephens
representative  who is now associated with Ernst & Young informed the Registrant
that the merger of Moore Stephens into Ernst & Young on May 5, 2005, effectively
constituted  their  resignation  as  the  Registrant's   independent  accountant
responsible for auditing its financial statements, and that effective as of such
date, Moore Stephens no longer acted as the Registrant's  independent registered
public accountant.  Therefore,  effective on May 5, 2005, Ernst & Young LLP, the
successor  firm to Moore  Stephens,  was engaged as the  independent  registered
public accounting firm of the Registrant.

     Moore Stephens'  report on the  Registrant's  financial  statements for the
year ended December 31, 2004 did not contain an adverse  opinion or a disclaimer
of opinion, nor was it qualified or modified as to uncertainty,  audit scope, or
accounting principles.

     During the period  covered  by the report of Moore  Stephens  and up to the
effective date of resignation,  the Registrant had no  disagreements  with Moore
Stephens,  whether or not resolved,  on any matter of  accounting  principles or
practices, financial statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of Moore Stephens, would have
caused  Moore   Stephens  to  make  reference  to  the  subject  matter  of  the
disagreement in connection with its reports.

     During the  Registrant's  previous two fiscal years and up to the effective
date of resignation, the Registrant did not consult with Ernst & Young regarding
any of the items described under Item  304(a)(1)(iv)(B),  Item 304(a)(2) or Item
304(b) of Regulation S-B.

     The  Registrant  has provided  Moore  Stephens  with a copy of this report.
Attached as Exhibit 16.1 is a copy of a letter from Moore Stephens agreeing with
the statements made in this report.

SECTION 9.  FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01  Financial Statements and Exhibits
--------------------------------------------

The following exhibits are furnished as part of this report:

          Exhibit 16.1 - Letter from Moore Stephens Ellis Foster Ltd.




<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                 DRAGON PHARMACEUTICAL INC.,
                                                 a Florida Corporation


Dated:  July 12, 2005                            /s/ Maggie Deng
                                                 -------------------------------
                                                 Maggie Deng
                                                 Chief Operating Officer
[{"type": "8-K", "sequence": "1", "filename": "form8k.txt", "secsgml_size_bytes": 5440}]
{"company-data": {"conformed-name": "DRAGON PHARMACEUTICAL INC", "cik": "0001075206", "assigned-sic": "2834", "irs-number": "650142474", "state-of-incorporation": "FL", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27937", "film-number": "05960040"}, "business-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "city": "VANCOUVER BC V6C 1X8", "state": "A1", "zip": "V6E 2E9", "phone": "6046698817"}, "mail-address": {"street1": "543 GRANVILLE STREET SUITE 1200", "street2": "VANCOUVER BRITISH COLUMBIA CANADA V6C1X", "city": "VANCOUVER BRITISH CO", "state": "A1", "zip": "V6E 2E9"}, "former-company": {"former-conformed-name": "DRAGON PHARMACEUTICALS INC", "date-changed": "19991022"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    Form 8-K

                Current Report Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

        Date of Report (Date of earliest event reported): July 12, 2005

                           DRAGON PHARMACEUTICAL INC.
                           --------------------------
             (Exact name of registrant as specified in its charter)

           Florida                        0-27937                65-0142474
           -------                        -------                ----------
State or Other Jurisdiction of    (Commission File Number)     (IRS Employer
        Incorporation)                                       Identification No.)

       1055 Hastings Street, Suite 1900
         Vancouver, British Columbia                   V6E 2E9
         ----------------------------                  -------
(Address of Principal Executive Offices)             (Zip Code)

                                 (604) 669-8817
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material  pursuant to Rule 4a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))
SECTION 4.  MATTERS RELATED TO ACCOUNTANTS AND FINANCIAL STATEMENTS

Item 4.01 Changes in Registrant's Certifying Accountant
-------------------------------------------------------

     Dragon  Pharmaceutical  Inc.  (the  "Registrant")  was  informed  that  its
independent  registered  public  accounting  firm of Moore Stephens Ellis Foster
Ltd. ("Moore Stephens"),  merged with and into Ernst & Young LLP on May 5, 2005.
On July 10, 2005,  the  Registrant's  board of directors  formally  approved the
engagement of Ernst & Young as the Registrant's  independent  registered  public
accounting  firm  for  2005.  On  July  12,  2005,  the  former  Moore  Stephens
representative  who is now associated with Ernst & Young informed the Registrant
that the merger of Moore Stephens into Ernst & Young on May 5, 2005, effectively
constituted  their  resignation  as  the  Registrant's   independent  accountant
responsible for auditing its financial statements, and that effective as of such
date, Moore Stephens no longer acted as the Registrant's  independent registered
public accountant.  Therefore,  effective on May 5, 2005, Ernst & Young LLP, the
successor  firm to Moore  Stephens,  was engaged as the  independent  registered
public accounting firm of the Registrant.

     Moore Stephens'  report on the  Registrant's  financial  statements for the
year ended December 31, 2004 did not contain an adverse  opinion or a disclaimer
of opinion, nor was it qualified or modified as to uncertainty,  audit scope, or
accounting principles.

     During the period  covered  by the report of Moore  Stephens  and up to the
effective date of resignation,  the Registrant had no  disagreements  with Moore
Stephens,  whether or not resolved,  on any matter of  accounting  principles or
practices, financial statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of Moore Stephens, would have
caused  Moore   Stephens  to  make  reference  to  the  subject  matter  of  the
disagreement in connection with its reports.

     During the  Registrant's  previous two fiscal years and up to the effective
date of resignation, the Registrant did not consult with Ernst & Young regarding
any of the items described under Item  304(a)(1)(iv)(B),  Item 304(a)(2) or Item
304(b) of Regulation S-B.

     The  Registrant  has provided  Moore  Stephens  with a copy of this report.
Attached as Exhibit 16.1 is a copy of a letter from Moore Stephens agreeing with
the statements made in this report.

SECTION 9.  FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01  Financial Statements and Exhibits
--------------------------------------------

The following exhibits are furnished as part of this report:

          Exhibit 16.1 - Letter from Moore Stephens Ellis Foster Ltd.
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                 DRAGON PHARMACEUTICAL INC.,
                                                 a Florida Corporation

Dated:  July 12, 2005                            /s/ Maggie Deng
                                                 -------------------------------
                                                 Maggie Deng
                                                 Chief Operating Officer